文献速递临床试验与 GCP流行病学与生物统计

妊娠期糖尿病筛查的实用随机临床试验

A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening.
PubMed 文献 · N Engl J Med · 2021-01-01

该实用随机试验比较一步法与两步法筛查妊娠期糖尿病,共随机分配23792名孕妇。一步法组诊断率16.5%,两步法组8.5%(未调整相对风险1.94;97.5%CI 1.79-2.11)。但两组在大于胎龄儿、围产期复合结局、妊娠期高血压或子痫前期及初次剖宫产率上无显著差异。

要点

  • 一步法筛查的妊娠期糖尿病诊断率显著高于两步法(16.5% vs 8.5%)。
  • 两种筛查方法在围产期和母体并发症的主要结局上无显著差异。
  • 意向性治疗分析及逆概率加权后结果均无实质性改变。

核心结论

  • 一步法筛查虽增加妊娠期糖尿病诊断,但未显著降低围产期和母体并发症风险。

研究设计与样本

  • 实用随机临床试验,在两家医疗系统内对所有接受产检的孕妇进行随机分组,比较一步法与两步法筛查。
  • 共23792名孕妇接受随机化,试验期间多次妊娠者可被分配至不止一种筛查类型。

主要发现

  • 一步法组妊娠期糖尿病诊断率为16.5%,两步法组为8.5%(未调整相对风险1.94;97.5%CI 1.79-2.11)。
  • 大于胎龄儿发生率分别为8.9%和9.2%(相对风险0.95;97.5%CI 0.87-1.05)。
  • 围产期复合结局发生率分别为3.1%和3.0%(相对风险1.04;97.5%CI 0.88-1.23)。
  • 妊娠期高血压或子痫前期发生率分别为13.6%和13.5%(相对风险1.00;97.5%CI 0.93-1.08)。
  • 初次剖宫产率分别为24.0%和24.6%(相对风险0.98;97.5%CI 0.93-1.02)。

关键数值与推荐

  • 一步法筛查:空腹口服75g葡萄糖后测血糖行糖耐量试验。
  • 两步法筛查:非空腹口服50g葡萄糖后测血糖行糖筛查试验,阳性者再空腹口服100g葡萄糖行糖耐量试验。
  • 妊娠期糖尿病治疗方案与两种筛查方法一致。

临床怎么用

  • 临床选择筛查方法时需权衡诊断率与后续管理负担,一步法诊断更多但未改善围产结局。

局限性

  • 一步法组仅66%遵守分配筛查,两步法组92%遵守,依从性差异可能影响结果。
  • 试验期间多次妊娠者可被分配至不同筛查类型,可能影响组间独立性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gestational diabetes mellitus is common and is associated with an increased risk of adverse maternal and perinatal outcomes. Although experts recommend universal screening for gestational diabetes, consensus is lacking about which of two recommended screening approaches should be used. METHODS: We performed a pragmatic, randomized trial comparing one-step screening (i.e., a glucose-tolerance test in which the blood glucose level was obtained after the oral administration of a 75-g glucose load in the fasting state) with two-step screening (a glucose challenge test in which the blood glucose level was obtained after the oral administration of a 50-g glucose load in the nonfasting state, followed, if positive, by an oral glucose-tolerance test with a 100-g glucose load in the fasting state) in all pregnant women who received care in two health systems. Guidelines for the treatment of gestational diabetes were consistent with the two screening approaches. The primary outcomes were a diagnosis of gestational diabetes, large-for-gestational-age infants, a perinatal composite outcome (stillbirth, neonatal death, shoulder dystocia, bone fracture, or any arm or hand nerve palsy related to birth injury), gestational hypertension or preeclampsia, and primary cesarean section. RESULTS: A total of 23,792 women underwent randomization; women with more than one pregnancy during the trial could have been assigned to more than one type of screening. A total of 66% of the women in the one-step group and 92% of those in the two-step group adhered to the assigned screening. Gestational diabetes was diagnosed in 16.5% of the women assigned to the one-step approach and in 8.5% of those assigned to the two-step approach (unadjusted relative risk, 1.94; 97.5% confidence interval [CI], 1.79 to 2.11). In intention-to-treat analyses, the respective incidences of the other primary outcomes were as follows: large-for-gestational-age infants, 8.9% and 9.2% (relative risk, 0.95; 97.5% CI, 0.87 to 1.05); perinatal composite outcome, 3.1% and 3.0% (relative risk, 1.04; 97.5% CI, 0.88 to 1.23); gestational hypertension or preeclampsia, 13.6% and 13.5% (relative risk, 1.00; 97.5% CI, 0.93 to 1.08); and primary cesarean section, 24.0% and 24.6% (relative risk, 0.98; 97.5% CI, 0.93 to 1.02). The results were materially unchanged in intention-to-treat analyses with inverse probability weighting to account for differential adherence to the screening approaches. CONCLUSIONS: Despite more diagnoses of gestational diabetes with the one-step approach than with the two-step approach, there were no significant between-group differences in the risks of the primary outcomes relating to perinatal and maternal complications. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ScreenR2GDM ClinicalTrials.gov number, NCT02266758.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Hillier TA, Pedula KL, Ogasawara KK, et al. A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening. N Engl J Med. 2021. PMID: 33704936. doi:10.1056/NEJMoa2026028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。